Jazaeri Farahnaz, Sheibani Mohammad, Nezamoleslami Sadaf, Moezi Leila, Dehpour Ahmad-Reza
Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2021 Spring;20(2):1-21. doi: 10.22037/ijpr.2020.113362.14254.
Drug-induced cholestasis is the main type of liver disorder accompanied by high morbidity and mortality. Evidence for the role of hepatobiliary pumps in the cholestasis patho-mechanism is constantly increasing. Recognition of the interactions of chemical agents with these transporters at the initial phases of drug discovery can help develop new drug candidates with low cholestasis potential. This review delivers an outline of the role of these transport proteins in bile creation. It addresses the pathophysiological mechanism for drug-induced cholestasis. models, including cell-based and membrane-based approaches and models such as genetic knockout animals, are considered. The benefits and restrictions of each model are discussed in this review. Current understandings into the cellular and molecular process that control the activity of hepatobiliary pumps have directed to a better understanding of the pathophysiology of drug-induced cholestasis. A combination of monitoring for transport interaction, predicting systems, and consideration of and metabolic and physicochemical properties must cause more effective monitoring of possible liver problems.
药物性胆汁淤积是主要的肝脏疾病类型,发病率和死亡率都很高。肝胆转运蛋白在胆汁淤积发病机制中的作用证据不断增加。在药物研发的初始阶段认识化学药物与这些转运蛋白的相互作用,有助于开发胆汁淤积潜力低的新候选药物。本综述概述了这些转运蛋白在胆汁生成中的作用。探讨了药物性胆汁淤积的病理生理机制。考虑了基于细胞和基于膜的方法等模型以及基因敲除动物等模型。本综述讨论了每种模型的优缺点。目前对控制肝胆转运蛋白活性的细胞和分子过程的理解,有助于更好地理解药物性胆汁淤积的病理生理学。结合转运相互作用监测、预测系统以及考虑代谢和物理化学性质,必须能更有效地监测可能出现的肝脏问题。